Validation and Refinement of the Baveno VI Criteria for Ruling Out High-Risk Varices

Table 1

Validation of the Baveno VI criteria.

Author	Research population (, etiology)	Prevalence of HRV (, %)	Spared endoscopy	Missed HRVs/saved endoscopies	Missed HRVs/total HRVs
Maurice [48]	310, mixed	15 (5%)	102/310 (33.0%)	2/102 (2.0%)	2/15 (13.3%)
Jangouk [66]	262, mixed US cohort (161)	14 (9%)	41/161 (25.4%)	0/41 (0%)	0/14 (0%)
	Italian cohort (101)	17 (17%)	16/101 (15.8%)	0/16 (0%)	0/17 (0%)
Sousa [72]	104, mixed	9 (9%)	48/104 (46.2%)	0/48 (0%)	0/9 (0%)
Wong [58]	127, mixed	11 (9%)	105/127 (82.7%)	1/105 (1.0%)	1/11 (9.1%)
Petta [32]	790, NAFLD
	Training cohort (314)	32 (10%)	106/314 (33.8%)	1/106 (0.9%)	1/32 (3.1%)
	Validation cohort (338)	45 (13%)	113/338 (33.4%)	5/113 (4.4%)	5/45 (11.1%)
Bae [51]	282, mixed	55 (20%)	78/282 (27.6%)	3/78 (3.8%)	3/55 (5.5%)
Colecchia [63]	498, mixed
	Internal cohort (240)	46 (19%)	52/240 (21.7%)	1/52 (1.9%)	1/46 (2.2%)
	External cohort (115)	15 (13%)	19/115 (16.5%)	0/19 (0%)	0/15 (0%)
Tosetti [68]	442, mixed	31 (7%)	86/442 (19.5%)	0/86 (0%)	0/31 (0%)
Lee [53]	1218, mixed	249 (20%)	313/1218 (25.7%)	6/313 (1.9%)	6/249 (2.4%)
Stefanescu [64]	185, mixed	43 (23%)	15/185 (8.1%)	0/15 (0%)	0/43 (0%)
Gaete [73]	300, mixed	54 (18%)	95/300 (31.7%)	1/95 (1.1%)	1/54 (1.9%)
Moctezuma-Velazquez [33]	227, PBC, PSC	30 (13%)	82/227 (36.1%)	0/82 (0%)	0/30 (0%)
Protopapas [71]	107, mixed	22 (21%)	13/107 (12.1%)	0/13 (0%)	0/22 (0%)

Note: HRV—high-risk varices; NAFLD—nonalcoholic fatty liver disease; PBC—primary biliary cholangitis; PSC—primary sclerosing cholangitis.